Compare BLNK & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | LONA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 71.2M |
| IPO Year | 2008 | 2020 |
| Metric | BLNK | LONA |
|---|---|---|
| Price | $0.58 | $6.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.33 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.0M | 38.3K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $4.21 |
| 52 Week High | $2.65 | $14.21 |
| Indicator | BLNK | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 47.88 |
| Support Level | $0.57 | $6.86 |
| Resistance Level | $0.62 | $8.57 |
| Average True Range (ATR) | 0.03 | 0.66 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 67.73 | 37.79 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.